GILD · Gilead Sciences, Inc.

S&P 500 #77 · NASDAQ-100 #27 · Nasdaq

Risiko 3/10 · Value / Pharma Income · $134.32 ▲ 2.91%

Kennzahlen

• Price $134.32
• Market cap $166.8B
• P/E (ttm) 18.27
• Div yield 2.51%
• 52-wk range $108.46 – $157.29
• Index rank #77 / #27

Wichtigste Risiken

• Patent cliff on Biktarvy (post-2030) (Future earnings) — MED
• Oncology pipeline execution risk (Growth) — MED
• HIV franchise maturation / generic exposure (Long-term revenue) — MED
• Drug pricing political risk (Margins) — MED

Fazit

Gilead is attractively valued at 17x trailing earnings with a 2.6% yield, fresh FDA wins for Trodelvy, and a leading HIV franchise — though longer-term patent cliffs remain a watch item.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.